These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17633790)

  • 1. The FDA's assessment of follow-on protein products: a historical perspective.
    Woodcock J; Griffin J; Behrman R; Cherney B; Crescenzi T; Fraser B; Hixon D; Joneckis C; Kozlowski S; Rosenberg A; Schrager L; Shacter E; Temple R; Webber K; Winkle H
    Nat Rev Drug Discov; 2007 Jun; 6(6):437-42. PubMed ID: 17633790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Food and Drug Administration's Role in Dermatologic Drug Development.
    Lewis FS; Marcus KA
    Dermatol Clin; 2022 Jul; 40(3):249-263. PubMed ID: 35750409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval.
    Kesselheim AS; Eddings W; Raj T; Campbell EG; Franklin JM; Ross KM; Fulchino LA; Avorn J; Gagne JJ
    PLoS One; 2016; 11(10):e0163339. PubMed ID: 27768700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic issues with follow-on protein products.
    Lanthier M; Behrman R; Nardinelli C
    Nat Rev Drug Discov; 2008 Sep; 7(9):733-7. PubMed ID: 18654570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways.
    Klein K; Borchard G; Shah VP; Flühmann B; McNeil SE; de Vlieger JSB
    Ann N Y Acad Sci; 2021 Oct; 1502(1):5-13. PubMed ID: 34296458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The US Food and drug administration: drug information resource for formulary recommendations.
    Marchand HC; Ros BJ; Fine AM; Kremzner ME
    J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization.
    Berlin RJ
    Am J Public Health; 2009 Sep; 99(9):1693-8. PubMed ID: 19372515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. We really need to talk: adapting FDA processes to rapid change.
    Lykken S
    Food Drug Law J; 2013; 68(4):357-99, i. PubMed ID: 24552079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Science, law, and politics in the Food and Drug Administration's genetically engineered foods policy: FDA's 1992 policy statement.
    Pelletier DL
    Nutr Rev; 2005 May; 63(5):171-81. PubMed ID: 15971412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scientific and legal viability of follow-on protein drugs.
    Dudzinski DM; Kesselheim AS
    N Engl J Med; 2008 Feb; 358(8):843-9. PubMed ID: 18287608
    [No Abstract]   [Full Text] [Related]  

  • 19. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen.
    Park SS; Park J; Ko J; Chen L; Meriage D; Crouse-Zeineddini J; Wong W; Kerwin BA
    J Pharm Sci; 2009 May; 98(5):1688-99. PubMed ID: 18781649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying The Food And Drug Administration's rulemaking delays highlights the need for transparency.
    Hwang TJ; Avorn J; Carpenter D; Kesselheim AS
    Health Aff (Millwood); 2014 Feb; 33(2):309-15. PubMed ID: 24493775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.